Malaria is one of the worst sicknesses to affect humankind. For centuries there was no specific treatment, and it was not until the seventeenth century that Spanish colonisers brought back from Peru tree bark from which quinine was later extracted. In the twentieth century, synthetic alternatives to quinine were developed. Of these, chloroquine was the most successful, but by the 1970s widespread resistance had developed and the world was left without an effective treatment for malaria. During the same decade Chinese scientists extracted from sweet wormwood plant the drug artemisinin, which has proved to be very effective against chloroquine-resistant malarial parasites. The use of a combination therapy including artemisinin has made it possible to contemplate the eradication of malaria. Efforts to produce a stable and inexpensive supply of artemisinin are under way.
Introduction Clinical practice guidelines (CPGs), statements that include recommendations intended to optimise patient care, play a critical role in standardising and improving treatment outcomes based on best evidence. It is currently unclear how many CPGs are available globally to assist clinicians in the management of patients with skin disease. Objective Our aim was to search for and identify CPGs for dermatological conditions with the highest burden globally. Methods We adapted a list of 12 dermatological conditions with the highest burden from the Global Burden of Disease (GBD) study 2019. A broad systematic literature search was conducted to identify CPGs published between October 2014 to October 2019. The scoping review was conducted and reported in accordance with the PRISMA framework. Results A total of 226 CPGs were included. Melanoma had the greatest representation in the CPGs, followed by dermatitis and psoriasis. Skin cancers had the highest CPGs representation overall but with lower GBD disease burden ranking. There was an uneven distribution by geographical region, with resource‐poor settings being under‐represented. The CPGs’ skin disease categories correlated weakly with the GBD disability‐adjusted life‐years metrics. 89 CPGs did not have funding disclosures and 34 CPGs were behind a paywall. Conclusion The global production of dermatology CPGs showed wide variation in geographical representation, article accessibility and funding reporting. The number of skin disease CPGs were not commensurate with its disease burden. Future work will critically appraise the methodology and quality of dermatology CPGs and lead to the production of an accessible online resource summarising these findings.
Laser Induced Breakdown spectroscopy (LIBS) of Tantalum (Ta) plasma has been investigated. For this purpose Q-switched Nd: YAG laser pulses (λ ∼ 1064 nm, τ ∼ 10 ns) of maximum pulse energy of 100 mJ have been employed as an ablation source. Ta targets were exposed under the ambient environment of various gases of Ar, mixture (CO2: N2: He), O2, N2, and He under various filling pressure. The emission spectrum of Ta is observed by using LIBS spectrometer. The emission intensity, excitation temperature, and electron number density of Ta plasma have been evaluated as a function of pressure for various gases. Our experimental results reveal that the optical emission intensity, the electron temperature and density are strongly dependent upon the nature and pressure of ambient environment. The SEM analysis of the ablated Ta target has also been carried out to explore the effect of ambient environment on the laser induced grown structures. The growth of grain like structures in case of molecular gases and cone-formation in case of inert gases is observed. The evaluated plasma parameters by LIBS analysis such as electron temperature and the electron density are well correlated with the surface modification of laser irradiated Ta revealed by SEM analysis.
13 July 2024 in Journal of the European Academy of Dermatology and Venereology
Background: There has been a global rise in cases of dermatophytosis and, in particular, recalcitrant and recurrent cases on tinea of the glabrous skin. This phenomenon, particularly prevalent in India, has been linked to the concerning rise of antifungal resistance. The challenge is amplified by a dearth of comprehensive, international data to understand the global scope and characteristics of such cases.Objectives: This study aims to collate international insights, focusing on areas outside Europe (as this was previously published), to map the extent and characteristics of clinical and, where possible, laboratory confirmed tinea of the glabrous skin through an online survey administered to dermatologists globally.Methods: An online survey was distributed from February 2022 to July 2023 and captured data on respondents' experience of recalcitrant and recurrent tinea of the glabrous skin over the preceding 3 years.Results: A total of 260 responses were received spreads across 36 countries, excluding Europe. In total, 91.7% reported seeing cases of recalcitrant or recurrent tinea of the glabrous skin over the preceding 3 years. Common anatomical sites affected were the trunk and groin. T. mentagrophytes and T. rubrum were the predominant species implicated, and there were low rates of laboratory confirmed dermatophyte resistance.Conclusions: The high rates of reported recalcitrant and recurrent tinea of the glabrous skin underscore an urgent need for global collaborative efforts and enhanced diagnostic measures. The findings advocate for the establishment of a standardized global disease registry, regulation of over‐the‐counter antifungal and steroid combinations, correlation of clinical suspicion with laboratory confirmed drug resistance and exploration of alternative therapeutic strategies to mitigate the burgeoning challenge of dermatophyte resistance.
Background: An increase in the number of recurrent and recalcitrant dermatophytoses calls for a tool to guide the clinician to correlate in vitro minimum inhibitory concentration (MIC) data, antifungal treatment with clinical outcomes. This systematic review aims to explore a possible correlation between one aspect of this, previous antifungal exposure, and clinical outcomes. Methods: A systematic literature search for articles on previous antifungal treatment, treatment outcome, susceptibility methods used, organism (genus/species), and MIC values was conducted. Results: A total of 720 records were identified of which 19 articles met the inclusion criteria. Forty percent of the cases had contact with or travel to India, 28% originated from or had traveled to other countries where treatment unresponsive tinea infections had been reported. Tinea corporis was the most common clinical presentation and the species involved were Trichophyton (T.) indotineae and T. rubrum, followed by T. mentagrophyte/interdigitale complex and T. tonsurans. Nearly all patients had previously been exposed to one or more antifungals. The studies were too heterogeneous to perform a statistical analysis to test if previous antifungal exposure was related to resistance. Conclusions: Only a few studies were identified, which had both sufficient and robust data on in vitro susceptibility testing and clinical treatment failure. Further research on the value of susceptibility testing to improve clinical practice in the management of dermatophyte infections is needed.
10 September 2024 in British Journal of Dermatology
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of Behçets. The document aims to offer an appraisal of all relevant literature up to 25 August 2023 focusing on any key developments; to address important, practical clinical questions relating to the primary guideline objective; and to provide guideline recommendations and appropriate research recommendations.